Share on StockTwits

Several investment firms have updated their stock ratings and price targets on shares of SAGE Therapeutics (NASDAQ: SAGE) in the last week:

  • SAGE Therapeutics is now covered by analysts at Goldman Sachs. They set a “neutral” rating and a $38.00 price target on the stock.
  • SAGE Therapeutics is now covered by analysts at Canaccord Genuity. They set a “buy” rating and a $40.00 price target on the stock.
  • SAGE Therapeutics is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $42.00 price target on the stock.
  • SAGE Therapeutics is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $46.00 price target on the stock.

SAGE Therapeutics Inc (NASDAQ:SAGE) traded down 0.48% on Thursday, hitting $29.00. The stock had a trading volume of 4,557 shares. SAGE Therapeutics Inc has a 52-week low of $24.25 and a 52-week high of $34.88. The stock has a 50-day moving average of $28.82 and a 200-day moving average of $28.82. The company’s market cap is $723.9 million.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, August 14th. The company reported ($4.57) earnings per share for the quarter, missing the analysts’ consensus estimate of ($1.23) by $3.34. On average, analysts predict that SAGE Therapeutics Inc will post $-2.00 earnings per share for the current fiscal year.

SAGE Therapeutics, Inc is a biopharmaceutical company. The Company is focused on development and commercialization of therapies for the treatment of life-threatening, rare central nervous system (NASDAQ:SAGE) disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.